2-(3-Fluorophenyl)-1-[[1-(3-fluorophenyl)triazol-4-yl]methyl]benzimidazole | 1096130-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(3-Fluorophenyl)-1-[[1-(3-fluorophenyl)triazol-4-yl]methyl]benzimidazole
• CAS: 1096130-17-4
• 化学式: C₂₂H₁₅F₂N₅
• 分子量: 387.391
• InChiKey: LUZHTXYBQCULIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  48.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(3-氟苯基)-1H-苯并咪唑 、 4-(Bromomethyl)-1-(3-fluorophenyl)triazole 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-(3-Fluorophenyl)-1-[[1-(3-fluorophenyl)triazol-4-yl]methyl]benzimidazole
  参考文献：
  名称：

  Clubbed [1,2,3] triazoles by fluorine benzimidazole: A novel approach to H37Rv inhibitors as a potential treatment for tuberculosis

  摘要：

  A Novel Clubbed [1,2,3] triazoles with. uorine benzimidazole series of H37Rv strain inhibitors, potentially useful for the treatment of tuberculosis is disclosed on the basis of promising results of preliminary antimicrobial study. Evaluation of the SAR of substitution within these series has followed the identi. cation of a range of compounds. Some of the derivatives are under further evaluation showing better considerable activity compared to rifampin. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.096

文献信息

• Clubbed [1,2,3] triazoles by fluorine benzimidazole: A novel approach to H37Rv inhibitors as a potential treatment for tuberculosis
  作者：Charansingh Gill、Ganesh Jadhav、Mohammad Shaikh、Rajesh Kale、Anant Ghawalkar、Deepak Nagargoje、Mahendra Shiradkar

  DOI：10.1016/j.bmcl.2008.09.096

  日期：2008.12

  A Novel Clubbed [1,2,3] triazoles with. uorine benzimidazole series of H37Rv strain inhibitors, potentially useful for the treatment of tuberculosis is disclosed on the basis of promising results of preliminary antimicrobial study. Evaluation of the SAR of substitution within these series has followed the identi. cation of a range of compounds. Some of the derivatives are under further evaluation showing better considerable activity compared to rifampin. (C) 2008 Elsevier Ltd. All rights reserved.